Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BNGO | Common Stock | Options Exercise | $22.7K | +44.5K | +320.07% | $0.51 | 58.4K | Jul 7, 2022 | Direct |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BNGO | Stock Option (Right to Buy) | Options Exercise | $0 | -44.5K | -100% | $0.00* | 0 | Jul 7, 2022 | Common Stock | 44.5K | $0.51 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | The shares vested in equal monthly installments over a one year period such that the option became fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). |
F2 | The acquisition of the reported option was reported in a Form 4 filed on July 2, 2020, which mistakenly reported the expiration date as 06/30/2029. |